CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe

[1]  C. Masimirembwa,et al.  Impact of gender, weight and CYP2B6 genotype on efavirenz exposure in patients on HIV/AIDS and TB treatment: Implications for individualising therapy , 2012 .

[2]  L. Waters,et al.  Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals , 2012, AIDS.

[3]  Yusuke Nakamura,et al.  CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans , 2012, European Journal of Clinical Pharmacology.

[4]  Daniel Röshammar,et al.  In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. , 2011, British journal of clinical pharmacology.

[5]  V. Haufroid,et al.  Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. , 2010, Pharmacogenomics.

[6]  D. Clifford,et al.  Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. , 2010, The Journal of infectious diseases.

[7]  T. Shioda,et al.  Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults , 2010, AIDS research and therapy.

[8]  K. Cohen,et al.  Management of individuals requiring antiretroviral therapy and TB treatment , 2010, Current opinion in HIV and AIDS.

[9]  L. Milani,et al.  A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. , 2009, British journal of clinical pharmacology.

[10]  D. Clifford,et al.  Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s) , 2009, HIV clinical trials.

[11]  K. Sagoe,et al.  CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients , 2009, AIDS.

[12]  F. Wit,et al.  Efavirenz Dose Reduction Is Safe in Patients With High Plasma Concentrations and May Prevent Efavirenz Discontinuations , 2009, Journal of acquired immune deficiency syndromes.

[13]  K. Ruxrungtham,et al.  Body Weight Cutoff for Daily Dosage of Efavirenz and 60-Week Efficacy of Efavirenz-Based Regimen in Human Immunodeficiency Virus and Tuberculosis Coinfected Patients Receiving Rifampin , 2009, Antimicrobial Agents and Chemotherapy.

[14]  M. J. García,et al.  Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients , 2009, Antimicrobial Agents and Chemotherapy.

[15]  A. Telenti,et al.  Pharmacogenetics‐Based Population Pharmacokinetic Analysis of Efavirenz in HIV‐1‐Infected Individuals , 2009, Clinical pharmacology and therapeutics.

[16]  Huldrych F. Günthard,et al.  In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function , 2009, Pharmacogenetics and genomics.

[17]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[18]  C. Leen,et al.  Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication , 2008, Antiviral therapy.

[19]  T. Harrer,et al.  Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. , 2008, The Journal of antimicrobial chemotherapy.

[20]  Prosper Chonzi,et al.  High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe , 2008, European Journal of Clinical Pharmacology.

[21]  S. Matsushita,et al.  Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  M. Schwab,et al.  Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. , 2007, Pharmacogenomics.

[23]  A. Matteelli,et al.  Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. , 2007, Current HIV research.

[24]  M Schwab,et al.  Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals , 2007, Clinical pharmacology and therapeutics.

[25]  S. Khoo,et al.  Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. , 2006, The Journal of antimicrobial chemotherapy.

[26]  D. Ward,et al.  Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. , 2006, AIDS patient care and STDs.

[27]  R. Farinotti,et al.  Efavirenz Does Not Interact with the ABCB1 Transporter at the Blood—Brain Barrier , 2006, Pharmaceutical Research.

[28]  F. Gutiérrez,et al.  Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  M. Hirsch,et al.  Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. , 2005, The Journal of infectious diseases.

[30]  T. Harrison,et al.  Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all , 2005, AIDS.

[31]  V. Soriano,et al.  Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Catia Marzolini,et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.

[33]  S. Oka,et al.  Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. , 2004, Biochemical and biophysical research communications.

[34]  J. Schubert,et al.  No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. , 2003, European journal of medical research.

[35]  B. Ring,et al.  Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression , 2003, Journal of Pharmacology and Experimental Therapeutics.

[36]  David A. Flockhart,et al.  The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[37]  Jacques Fellay,et al.  Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection , 2003, Clinical pharmacology and therapeutics.

[38]  Mats O. Karlsson,et al.  Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[39]  David A. Flockhart,et al.  Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A , 2001, Antimicrobial Agents and Chemotherapy.

[40]  A. Telenti,et al.  Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .

[41]  M. O. Karlsson,et al.  The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[42]  C. Masimirembwa,et al.  Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe. , 2013, Current HIV research.

[43]  Huldrych F. Günthard,et al.  Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. , 2012, JAMA.

[44]  A. Sánchez Martín,et al.  Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV. , 2010, Clinical drug investigation.

[45]  Y. Nishimura,et al.  Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. , 2004, Journal of pharmacological sciences.

[46]  J. Pachón,et al.  Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis , 2002, Clinical pharmacokinetics.

[47]  L. Whitaker.  Treatment and Prevention , 1992 .